

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Anderson et al.

Appln. No.: 08/

921,060

Series Code

Filed: August 29, 1997

Hon. Commissioner of Patents

Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

Group Art Unit

1644

Examiner:

R. Schwadron

Atty. Dkt.

P

0275463

1992-30-0029CP2

M#

Client Ref

Appln. Title:

EX VIVO TREATMENT OF
ALLOGENIC AND XENOGENIC
DONOR T CELLS CONTAINING
COMPOSITIONS (BONE MARROW)
USING GP39 ANTAGONISTS AND
USE THEREOF

Date: February 28, 2003

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim	Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
A. <input checked="" type="checkbox"/> NOT made		**minus	0	0	x \$18/\$9 =	103/203
B. <input type="checkbox"/> Withdrawn		***minus	0	0	x \$84/\$42 =	102/202
C. <input type="checkbox"/> made herewith					+ \$280/\$140 =	104/204
D. <input type="checkbox"/> made previously						
2. Total Effective Claims						
3. Independent Claims						
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)						
5. Original due Date:						
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached						
7. Enter any previous extension fee paid since above original due date and subtract						
8. Extension Fee						
9. If Terminal Disclaimer attached, add Rule 20(d) official fee						
10. If IDS attached requires Official Fee under Rule 97 (c), add						
or if Rule 97(d) Request add						
11. After-Final Request Fee per rules 129(a) and 17(r)						
12. No. of additional inventions for examination per Rule 129(b)						
13. Request for Continued Examination (RCE)						
14. Petition fee for						
15. TOTAL FEE =						
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".						
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.						
18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.						

03/04/2003 CCHAU1 00000068 033975 08921060

01 FC:1251

110.00 CH

Our Deposit Account No. 03-3975)

(Our Order No. 037003

0275463

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robin L. Teskin

Reg. No. 35,030

P.O. Box 10500

McLean, VA 22102

Tel: (703) 905-2000

Sig:

Robin Teskin/Julie Broadus
47,447Fax:
Tel:(703) 905-2500
(703) 905-2200

Atty/Sec: RLT/RLG

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments



#79
RECEIVED
MAR 06 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Anderson et al.

Group Art Unit: 1644

Application Serial No. 08/921,060

Examiner: R. Schwadron

Filed: August 29, 1997

Title: *EX VIVO TREATMENT OF ALLOGENIC AND XENOGENIC DONOR T CELLS CONTAINING COMPOSITIONS (BONE MARROW) USING GP39 ANTAGONISTS AND USE THEREOF*

* * * * *

ELECTION RESPONSE

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action [Restriction Requirement] mailed on December 30, 2002, Applicants elect for purposes of examination with traverse the following:

- (1) the antibody heavy SEQ ID NO. 11 and
- (2) a method of using the antibody to deplete B cells.

The restriction is traversed on the basis that methods of treating B cell lymphoma and methods of B cell depletion will be substantially co-extensive, as will the search for only two different chemical antibody sequencers. Rejoinder is therefore requested.

Respectfully submitted,
PILLSBURY WINTHROP LLP

By: Robin Teskin/Julie Broadus
Robin L. Teskin 47,447
Registration No. 35,030

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2000
(703) 905-2500 Facsimile

Date: February 28, 2003
Attorney Reference: 037003-0275463
/rg